Top Markets
Coin of the day
Impel Pharmaceuticals Inc. Impel Pharmaceuticals Inc.

Impel Pharmaceuticals Inc.

IMPL
Xếp hạng trong cổ phiếu #37159
Impel Pharmaceuticals Inc. operates as a commercial-stage biopharmaceutical... Impel Pharmaceuticals Inc. operates as a commercial-stage biopharmaceutical firm, concentrating its efforts on creating and commercializing therapies for individuals in the United States who are affected by central nervous system (CNS) conditions. Leading its product portfolio is Trudhesa, an innovative upper nasal formulation of dihydroergotamine, specifically engineered for the prompt relief of acute migraine attacks. Furthermore, the company's development pipeline encompasses INP105, another upper nasal medication containing olanzapine, currently being advanced for the rapid treatment of agitation and aggressive behaviors associated with autism spectrum disorder. Impel is also progressing with INP107, an intranasal carbidopa/levodopa compound, which has already successfully concluded its Phase IIa clinical trial aimed at managing "OFF" episodes in Parkinson's disease patients. Initially established in 2008, the company was formerly known as Impel NeuroPharma, Inc. before rebranding to Impel Pharmaceuticals Inc. in April 2022. Its corporate headquarters are situated in Seattle, Washington.
Giá cổ phiếu
$0.1011
Đồng bộ lần cuối: 2024-01-16
Vốn hóa thị trường
$1.96M
Thay đổi (1 ngày)
1.10%
Thay đổi (1 năm)
0.00%
Quốc gia
US
Giao dịch Impel Pharmaceuticals Inc. (IMPL)

Danh mục

Lịch sử giá cổ phiếu của Impel Pharmaceuticals Inc. (IMPL)
Giá đóng cửa cao nhất: $0.10 vào 2024-01-01

Giá đóng cửa thấp nhất: $15.09 vào 2021-04-01
Lịch sử giá cổ phiếu của Impel Pharmaceuticals Inc. từ 2021 đến 2026
Hiệu suất giá cổ phiếu hàng năm
Năm Hiệu suất
2024 -63.47%
2023 -91.81%
2022 -64.07%
2021 0.00%
Giá cổ phiếu của các công ty hoặc đối thủ tương tự
Công ty Giá cổ phiếu Thay đổi 1năm% Quốc gia
$505.24 28.63%
US
$846.09 29.41%
NL
$731.69 6.47%
CH
$1.07K -6.40%
KR
$251.82 11.75%
BE